SecBot SecBot
SECBOTREPLAY Home › Report › MLYS

MLYS · CEO Jon Congleton files Form 144 to sell 75,000 shares valued at…

Mineralys Therapeutics, Inc. · 144 filed Jun 30, 2026 at 16:20 ET

At the news

NEUTRALIMPACT 3/10

144 filed Jun 30, 2026 at 16:20 ET

CEO Jon Congleton files Form 144 to sell 75,000 shares valued at ~$1.96M, sourced from RSU vestings. The planned sale is modest relative to the $2.2B market cap and his likely total holdings, but the ~$2.0M cash-out by the CEO is notable in light of Institutional 13F accumulation (8 adds, 1 new) and the lack of recent positive catalysts.

  • Insider: Jon Congleton, CEO of Mineralys Therapeutics, filed Form 144 on 6/30/2026 to sell 75,000 shares of common stock.
  • Estimated proceeds: ~$1,960,602 at filing (approx. $26.14/share based on recent trade data).
  • Shares to be sold were acquired through vesting of RSU awards on 7/10/2024 (24,619 shares), 10/10/2024 (35,954 shares), and 1/10/2025 (14,427 shares).
  • Congleton also received a separate RSU award of 75,000 shares on 3/31/2026 and additional shares on 4/13/2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access